Bone Biologics Corp
BBLGDrugs in Pipeline
6
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
JTA-004 intra-articular injection
Knee Osteoarthritis
JTA-004
Symptomatic Osteoarthritis of the Knee
TransCon CNP
Achondroplasia
ALLOB® cells with ceramic scaffold
Degenerative Disc Disease
ALLOB® implantation
Long Bone Delayed-Union Fracture
Navepegritide
Achondroplasia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
JTA-004 intra-articular injection | Phase 3 | Knee Osteoarthritis | - | - |
JTA-004 | Phase 3 | Symptomatic Osteoarthritis of the Knee | - | - |
TransCon CNP | Phase 3 | Achondroplasia | - | - |
ALLOB® cells with ceramic scaffold | Phase 2 | Degenerative Disc Disease | - | - |
ALLOB® implantation | Phase 2 | Long Bone Delayed-Union Fracture | - | - |
Navepegritide | Phase 2 | Achondroplasia | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Bone Biologics Corp's drug pipeline?→
CatalystAlert tracks 6 drug candidates in Bone Biologics Corp's (BBLG) pipeline across Phase 3, Phase 2. Its lead program is JTA-004 intra-articular injection (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Bone Biologics Corp's next FDA catalyst?→
Bone Biologics Corp's (BBLG) next tracked catalyst is a Earnings expected November 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BBLG biotech catalysts?→
Add BBLG to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Bone Biologics Corp's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.